• Group Underlying EBITDA expected between $259.0m and $264.0m
• Group Underlying EBIT expected between $30.0m and $35.0m
• Pathology costs contained, labour costs impacted by Fair Work Commission decision

Healius Limited (ASX: HLS) has announced a trading update for the financial year 2026 (FY 2026). The company now expects Group Underlying Earnings Before Tax and Depreciation (EBITDA) to be between $259.0m and $264.0m, and Group Underlying Earnings Before Interest and Tax (EBIT) to be between $30.0m and $35.0m. In the Pathology business, volumes grew by 1.2% and revenue grew by 3.5% for the first half of FY 2026. However, for the 10 months to April 2026, volumes have declined by 0.4% while revenue has grown by 2.4%. GP attendances declined by 1.5% for the first half of FY 2026 and by 1.0% for the period January to March 2026. Pathology costs have been contained to an increase of 1.1% for the 10 months to April 2026, a further reduction from the 1.9% reported as at December 2025.The company's Pathology labour costs will be impacted in Q4 2026 by $1.8m due to the Fair Work Commission's initial findings on gender-based undervaluation. Pathology Collectors received this increase from 1 April 2026, and Health Professionals will receive a phased increase over five years starting on 1 July 2026.Healius also announces that it has engaged UBS Securities Australia Limited to assist in exploring a sale of its Agilex Biolabs business, which continues to trade strongly with revenue growing by 13.7% for the year to date.The company also comments on the Federal Budget, noting that it contains no new funding for pathology, a sector already operating under an indexation freeze for most tests. The company states that inadequate funding has resulted in difficult decisions to cut staff, close collection centres and regional laboratories, and that charging out-of-pocket fees for pathology tests is the only viable option left to bridge the funding gap.Healius remains committed to supporting quality, affordable and accessible healthcare for all Australians through its unique footprint of centres and its 8,000+ employees.

Group Underlying EBITDA expected between $259.0m and $264.0m, and Group Underlying EBIT expected between $30.0m and $35.0m for FY 2026.